Health and Healthcare

Short Sellers Become More Wary of Big Biotech

The short interest data are out for the April 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or break them. A single failed clinical trial can mean disaster for a stock. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.

The tax day (April 15) short interest data have been compared with the previous figures, and for most of the selected stocks, short interest is down.

Amgen Inc. (NASDAQ: AMGN) saw its short interest drop to 9.75 million shares from the previous short interest reading of 10.3 million. The short interest for Amgen has risen to an elevated level after having taken a dip in recent settlement dates, recording the lowest levels on the year. Shares closed Friday at $167.91, in a 52-week trading range of $108.20 to $173.14.

ALSO READ: The 5 Most Shorted Nasdaq Stocks

Biogen Idec Inc. (NASDAQ: BIIB) saw its short interest fall to 2.6 million shares from the previous level of 2.79 million. The company is slowly approaching its lowest short interest readings back in November and seemingly returning to its recent historic levels. Shares closed Monday at $401.71, within a 52-week trading range of $275.39 to $480.18.

Celgene Corp. (NASDAQ: CELG) short interest increase only slightly for this settlement date, up to 14.68 million shares. The level for the previous settlement date was 14.60 million. Since March, Celgene has recorded two of its highest readings of the year, barring a spike last June. Shares of Celgene closed Monday at $118.71, in a 52-week trading range of $69.88 to $129.06.

Gilead Sciences Inc. (NASDAQ: GILD) saw its short interest remain relatively flat at 57.43 million shares, up from 57.31 million. Investors seem to have increased their pessimism compared to recent months. Shares closed Monday at $103.69, in a 52-week trading range of $72.77 to $116.83.

MannKind Corp. (NASDAQ: MNKD) saw its short interest increase to 96.88 million shares. The previous reading for short interest was 95.72 million. Short interest for MannKind appears to have steadily increased to its 52-week high. Shares closed Monday at $4.80, in a 52-week trading range of $4.45to $11.48.

Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) short interest decreased to 3.30 million shares, up from the past level of 3.45 million. This current reading and the most recent three are some of the highest on the new year. Shares closed Monday at $180.08, in a 52-week trading range of $147.81 to $203.30.

ALSO READ: More Declines in Solar, Alt Energy Short Interest

The Average American Is Losing Their Savings Every Day (Sponsor)

If you’re like many Americans and keep your money ‘safe’ in a checking or savings account, think again. The average yield on a savings account is a paltry .4% today, and inflation is much higher. Checking accounts are even worse.

Every day you don’t move to a high-yield savings account that beats inflation, you lose more and more value.

But there is good news. To win qualified customers, some accounts are paying more than10x this national average. That’s an incredible way to keep your money safe, and get paid at the same time. Our top pick for high yield savings accounts includes other benefits as well. It pays one time cash bonuses on deposits, and is FDIC insured.

Click here to see how much more you could be earning on your savings today. It takes just a few minutes and your money could be working for you.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.

AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.